Skip to main content

ADA: Once-Weekly Icodec Superior for Reduction in HbA1c

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, June 28, 2023 -- For patients with insulin-naive type 2 diabetes, once-weekly icodec is superior for reduction in hemoglobin A1c (HbA1c), according to a study published online June 24 in the Journal of the American Medical Association to coincide with the annual meeting of the American Diabetes Association, held from June 23 to 26 in San Diego.

Ildiko Lingvay, M.D., M.P.H., from the University of Texas Southwestern Medical Center in Dallas, and colleagues examined the efficacy and safety of once-weekly icodec versus once-daily insulin degludec in people with insulin-naive type 2 diabetes in a phase 3a trial conducted at 92 sites in 11 countries. Participants were randomly assigned to once-weekly icodec and once-daily placebo or once-daily degludec and once-weekly placebo (294 patients in each group).

The researchers found that the mean HbA1c level decreased from 8.6 to 7.0 percent at 26 weeks in the icodec group and from 8.5 to 7.2 percent in the degludec group (estimated treatment difference, −0.2 percentage points), confirming noninferiority and superiority. No significant between-group differences were seen in the change in fasting plasma glucose from baseline to week 26, mean weekly insulin dose during the last two weeks of treatment, or change in body weight from baseline to week 26. The icodec group had combined level 2 or 3 hypoglycemia rates that were numerically higher from week 0 to 31 and statistically significantly higher from week 0 to 26.

"When considering treatment with icodec insulin in clinical practice, the small added glycemic benefit and convenience of the once-weekly administration should be weighed against the small absolute risk of hypoglycemia," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Novo Nordisk, which manufactures once-weekly insulin icodec and funded the study.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Men Face More Diabetes Complications Than Women

FRIDAY, May 17, 2024 -- Men with diabetes have a greater risk for complications than women, irrespective of diabetes duration, according to a study published online May 16 in...

AI-Informed Health App Aids Diabetes Outcomes

WEDNSDAY, May 15, 2024 -- Use of an artificial intelligence (AI)-informed health app aids diabetes outcomes and cuts atherosclerotic cardiovascular disease (ASCVD) risk, according...

Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist

TUESDAY, May 14, 2024 -- One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.